

Special Issue

Clinical Trials in Gastroesophageal Cancer

Message from the Guest Editor

Clinical trials underpin modern clinical practice for patients with gastroesophageal cancer. Multimodality therapy remains the mainstay of treatment for gastroesophageal cancer, with the evidence for its effectiveness coming largely from recent clinical trials integrating immunotherapy into the therapeutic repertoire. However, clinical trials of gastroesophageal cancer are notoriously challenging, as several pitfalls are associated with the design and delivery of these trials in a complex cohort of patients with a highly heterogenous tumor. The field is developing even further as we move towards trials with a greater degree of international collaboration that include the introduction of novel endpoints, surgical and radiological quality assurance and the utilization of machine learning algorithms, warranting a Special Issue in this area. We invite the submission in the following areas:

- Clinical trials concerning the diagnosis or management of gastroesophageal cancer
- Challenges to undertaking trials in gastroesophageal cancer
- Quality assurance of interventions concerning gastroesophageal cancer

Guest Editor

Dr. Sheraz Rehan Markar

Nuffield Department of Surgery, University of Oxford, Oxford OX1 2JD, UK

Deadline for manuscript submissions

closed (23 February 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



mdpi.com/si/163193

Cancers

MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)